204 related articles for article (PubMed ID: 19233569)
1. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population.
Ezzikouri S; El Feydi AE; Afifi R; El Kihal L; Benazzouz M; Hassar M; Marchio A; Pineau P; Benjelloun S
Cancer Detect Prev; 2009; 32(5-6):380-5. PubMed ID: 19233569
[TBL] [Abstract][Full Text] [Related]
2. MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis.
Liu GY; Jiang DK; Shen SQ; Yu L
Arch Med Res; 2011 Feb; 42(2):149-55. PubMed ID: 21565629
[TBL] [Abstract][Full Text] [Related]
3. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
4. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
5. Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma.
Ezzikouri S; Essaid El Feydi A; Afifi R; Benazzouz M; Hassar M; Pineau P; Benjelloun S
Int J Biol Markers; 2011; 26(4):229-33. PubMed ID: 22180176
[TBL] [Abstract][Full Text] [Related]
6. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
Dharel N; Kato N; Muroyama R; Moriyama M; Shao RX; Kawabe T; Omata M
Clin Cancer Res; 2006 Aug; 12(16):4867-71. PubMed ID: 16914573
[TBL] [Abstract][Full Text] [Related]
7. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
[TBL] [Abstract][Full Text] [Related]
8. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yoon YJ; Chang HY; Ahn SH; Kim JK; Park YK; Kang DR; Park JY; Myoung SM; Kim DY; Chon CY; Han KH
Carcinogenesis; 2008 Jun; 29(6):1192-6. PubMed ID: 18390844
[TBL] [Abstract][Full Text] [Related]
9. MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population.
Wang X; Zhang X; Qiu B; Tang Y; Sun H; Ji H; Liu Y; Shi L; Song G; Yang Y
Liver Int; 2012 Aug; 32(7):1172-8. PubMed ID: 22413855
[TBL] [Abstract][Full Text] [Related]
10. Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population.
Ezzikouri S; El Feydi AE; Benazzouz M; Afifi R; El Kihal L; Hassar M; Akil A; Pineau P; Benjelloun S
Infect Genet Evol; 2009 Sep; 9(5):877-81. PubMed ID: 19465161
[TBL] [Abstract][Full Text] [Related]
11. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population.
Leu JD; Lin IF; Sun YF; Chen SM; Liu CC; Lee YJ
World J Gastroenterol; 2009 Nov; 15(44):5592-7. PubMed ID: 19938200
[TBL] [Abstract][Full Text] [Related]
12. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
13. Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma.
Acun T; Terzioğlu-Kara E; Konu O; Ozturk M; Yakicier MC
Mutat Res; 2010 Feb; 684(1-2):106-8. PubMed ID: 19954744
[TBL] [Abstract][Full Text] [Related]
14. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
[TBL] [Abstract][Full Text] [Related]
15. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
16. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
17. Associations of genetic variants in the transcriptional coactivators EP300 and PCAF with hepatocellular carcinoma.
Akil A; Ezzikouri S; El Feydi AE; Benazzouz M; Afifi R; Diagne AG; Benjouad A; Dejean A; Pineau P; Benjelloun S
Cancer Epidemiol; 2012 Oct; 36(5):e300-5. PubMed ID: 22709982
[TBL] [Abstract][Full Text] [Related]
18. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.
Lind H; Zienolddiny S; Ekstrøm PO; Skaug V; Haugen A
Int J Cancer; 2006 Aug; 119(3):718-21. PubMed ID: 16496380
[TBL] [Abstract][Full Text] [Related]
19. Association between SNP309 and del1518 Polymorphism in MDM2 Homologue and Esophageal Squamous Cell Carcinoma Risk in Chinese Population of Shandong Province.
Zhang L; Zhu Z; Wu H; Wang K
Ann Clin Lab Sci; 2015; 45(4):433-7. PubMed ID: 26275695
[TBL] [Abstract][Full Text] [Related]
20. MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: a meta-analysis.
Chen QW; Chen H; Cheng JS; Meng ZQ
Tumour Biol; 2014 May; 35(5):4147-51. PubMed ID: 24379140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
